Fintel reports that on October 3, 2025, TD Securities downgraded their outlook for Celestica (NYSE:CLS) from Buy to Hold.

In the closing of the recent trading day, Celestica (CLS) stood at $237.79, denoting a +1.04% move from the preceding trading day.

Celestica (CLS) ended the recent trading session at $251.69, demonstrating a +2.16% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of ...

Former MSP and land campaigner Andy Wightman claimed last month that Gresham House, through the partnerships that they ...

* Price is based on Glass's Information Services third party pricing data for the lowest priced Mercedes-Benz CLS-Class 2016 variant. The Price excludes costs such as stamp duty, other government ...

Campaigners urge the Scottish National Investment Bank to reconsider its £50m backing of Gresham House amid growing concerns over land speculation.

See how Concept Life Sciences accelerated early clinical trials by quickly transferring a client’s process and completing GMP ...

Celestica (CLS) closed the most recent trading day at $257.64, moving +1.12% from the previous trading session. This change outpaced the S&P 500's 0.55% loss on the day. Meanwhile, the Dow lost 0.19%, ...

Celestica rallied following blowout Q2 earnings and continues to benefit from AI tailwinds, but the stock now appears overextended after a swift 26% rally. Options activity and technical indicators ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Detailed price information for Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM-CN) from The Globe and Mail including charting and trades.